Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 256.78 M

Soleno Therapeutics, Inc. Cash and Short-Term Investments is USD 256.78 M for the quarter ending September 30, 2024, a 389.68% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Soleno Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 52.44 M.
Soleno Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 28.18 M, a -49.79% change year over year.
Soleno Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 56.14 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years